Latest period
$19.36B
YoY change
+13.7%
5Y CAGR
+16.5%
Peak year (2025)
$18.67B
Latest annual
$18.67B
Total Equity history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Latest: $18.67B
Total Equity growth chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Latest: +13.7%
Total Equity history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| 2025 | $18.67B | +13.7% | +$2.26B | ||
| 2024 | $16.41B | -6.7% | −$1.17B | ||
| 2023 | $17.58B | +26.4% | +$3.67B | ||
| 2022 | $13.91B | +37.7% | +$3.81B | ||
| 2021 | $10.10B | +16.3% | +$1.41B | ||
| 2020 | $8.69B | +42.8% | +$2.60B | ||
| 2019 | $6.09B | +37.2% | +$1.65B | ||
| 2018 | $4.44B | +118.6% | +$2.41B | ||
| 2017 | $2.03B | +75.4% | +$872.00M | ||
| 2016 | $1.16B | +23.0% | +$216.62M | ||
| 2015 | $939.97M | -12.6% | −$135.04M | ||
| 2014 | $1.08B | -20.7% | −$281.40M | ||
| 2013 | $1.36B | +35.8% | +$357.23M | ||
| 2012 | $999.18M | +27.0% | +$212.34M | ||
| 2011 | $786.84M | +56.1% | +$282.87M | ||
| 2010 | $503.97M | -54.0% | −$592.37M | ||
| 2009 | $1.10B | +359.0% | +$857.47M | ||
| 2008 | $238.87M | -12.0% | −$32.42M | ||
| 2007 | $271.30M | -46.4% | −$234.64M | ||
| 2006 | $505.94M | +111.5% | +$266.76M | ||
| 2005 | $239.18M | +574.9% | +$203.74M | ||
| 2004 | $35.44M | -81.6% | −$157.40M | ||
| 2003 | $192.84M | -49.1% | −$185.74M | ||
| 2002 | $378.58M | -20.4% | −$96.77M | ||
| 2001 | $475.35M | -7.5% | −$38.66M | ||
| 2000 | $514.01M | +145.7% | +$304.78M | ||
| 1999 | $209.23M | -15.0% | −$36.97M | ||
| 1998 | $246.20M | -10.8% | −$29.80M | ||
| 1997 | $276.00M | +111.0% | +$145.20M | ||
| 1996 | $130.80M | +53.3% | +$45.50M | ||
| 1995 | $85.30M | -19.1% | −$20.20M | ||
| 1994 | $105.50M | +113.1% | +$56.00M | ||
| 1993 | $49.50M | +12.8% | +$5.60M | ||
| 1992 | $43.90M | -15.9% | −$8.30M | ||
| 1991 | $52.20M | +903.8% | +$47.00M | ||
| 1990 | $5.20M | — | — |
- 2025$18.67B+13.7%
- 2024$16.41B-6.7%
- 2023$17.58B+26.4%
- 2022$13.91B+37.7%
- 2021$10.10B+16.3%
- 2020$8.69B+42.8%
- 2019$6.09B+37.2%
- 2018$4.44B+118.6%
- 2017$2.03B+75.4%
- 2016$1.16B+23.0%
- 2015$939.97M-12.6%
- 2014$1.08B-20.7%
- 2013$1.36B+35.8%
- 2012$999.18M+27.0%
- 2011$786.84M+56.1%
- 2010$503.97M-54.0%
- 2009$1.10B+359.0%
- 2008$238.87M-12.0%
- 2007$271.30M-46.4%
- 2006$505.94M+111.5%
- 2005$239.18M+574.9%
- 2004$35.44M-81.6%
- 2003$192.84M-49.1%
- 2002$378.58M-20.4%
- 2001$475.35M-7.5%
- 2000$514.01M+145.7%
- 1999$209.23M-15.0%
- 1998$246.20M-10.8%
- 1997$276.00M+111.0%
- 1996$130.80M+53.3%
- 1995$85.30M-19.1%
- 1994$105.50M+113.1%
- 1993$49.50M+12.8%
- 1992$43.90M-15.9%
- 1991$52.20M+903.8%
- 1990$5.20M—
Total Equity values are taken from Vertex Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's latest reported total equity is $19.36B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Vertex Pharmaceuticals (VRTX) total equity totalled $18.67B – grew 13.7% year-over-year.
Through 2020–2025 (5 years), Vertex Pharmaceuticals total equity delivered a +16.5% annualised rate; with mixed annual results across the window.
2025 marks the peak total equity at $18.67B, with the historical low of $5.20M recorded in 1990.
Vertex Pharmaceuticals Total Equity by Year
Vertex Pharmaceuticals Total Equity 2025: $18.67B
2025's total equity for Vertex Pharmaceuticals came in at $18.67B, grew 13.7% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Total Equity 2024: $16.41B
Vertex Pharmaceuticals posted total equity of $16.41B in 2024, declined 6.7% below 2023.
Vertex Pharmaceuticals Total Equity 2023: $17.58B
In 2023, Vertex Pharmaceuticals reported total equity of $17.58B, grew 26.4% from 2022.
Vertex Pharmaceuticals Total Equity 2022: $13.91B
Vertex Pharmaceuticals total equity in 2022 was $13.91B, surged 37.7% from 2021.
Vertex Pharmaceuticals Total Equity 2021: $10.10B
Vertex Pharmaceuticals total equity in 2021 was $10.10B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers by Total Equity
Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation